Lantheus Holdings’ 10% owner, Lantheus Alpha Therapy, LLC, sold 42,129 shares at $3.11 per share and held 11,521,296 shares afterward. The ownership figure matters to investors because it shows Alpha Therapy’s reported position following the sale, while a separate record lists 113,914 Perspective Therapeutics shares sold at $3.12 to $3.14.
Key Highlights
- The Lantheus transaction was dated September 2, 2026.
- A separate record lists 113,914 Perspective Therapeutics shares sold at prices ranging from $3.12 to $3.14 per share.
- Lantheus Alpha Therapy, LLC, is identified as a 10% owner of Perspective Therapeutics, Inc.
Filing
The filing reports the sale of 42,129 shares at $3.11 per share on 2 September 2026, with SEC transaction code S.
Reported Perspective Holdings The
filing also identifies Lantheus (NASDAQ: LNTH) Alpha Therapy, LLC as a 10% owner of Perspective Therapeutics, Inc (AMEX: CATX). Following the reported transaction, the LLC owned 11,521,296 shares of Perspective Therapeutics, Inc.
Separate Perspective Transaction A
separate transaction record lists the LLC’s sale of 113,914 shares of Perspective Therapeutics, Inc. across two separate transactions. Those shares were sold at prices ranging from $3.12 to $3.14 per share.
FAQs
Q: How many Lantheus Holdings shares did Alpha Therapy sell?
A: Lantheus Alpha Therapy, LLC sold 42,129 Lantheus Holdings shares at $3.11 per share. The reported post-transaction ownership was 11,521,296 shares.
Q: What was the Lantheus Holdings transaction price?
A: The Lantheus Holdings share sale was priced at $3.11 per share. The transaction involved the company’s 10% owner, Lantheus Alpha Therapy, LLC.
Q: How many Perspective Therapeutics shares did Alpha Therapy sell?
A: A separate record lists Lantheus Alpha Therapy, LLC selling 113,914 Perspective Therapeutics shares. Prices ranged from $3.12 to $3.14 per share.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.